Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Non-Current Deffered Revenue (2021 - 2022)

ADC Therapeutics has reported Non-Current Deffered Revenue over the past 2 years, most recently at $215.9 million for Q4 2022.

  • Quarterly results put Non-Current Deffered Revenue at $215.9 million for Q4 2022, down 3.05% from a year ago — trailing twelve months through Dec 2022 was $215.9 million (down 3.05% YoY), and the annual figure for FY2022 was $215.9 million, down 3.05%.
  • Non-Current Deffered Revenue reached $215.9 million in Q4 2022 per ADCT's latest filing, down from $222.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $222.7 million in Q4 2021 and bottomed at $215.9 million in Q4 2022.